Log In
BCIQ
Print this Print this
 

ABP 215

Also known as: bevacizumab

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBiosimilar of Avastin bevacizumab, a humanized mAb against VEGF
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat metastatic non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerAllergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/02/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today